Halozyme Therapeutics Ownership | Who Owns Halozyme Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Halozyme Therapeutics Ownership Summary

Halozyme Therapeutics is owned by 53.28% institutional investors, 1.14% insiders, and 45.59% retail investors. Blackrock is the largest institutional shareholder, holding 13.88% of HALO shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.27% of its assets in Halozyme Therapeutics shares.

HALO Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Halozyme Therapeutics	53.28%	1.14%	45.59%
Sector	Healthcare Stocks	232.01%	10.74%	-142.75%
Industry	Biotech Stocks	381.47%	10.55%	-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	17.62M	13.88%	$922.58M
Blackrock funding, inc. /de	13.15M	11.22%	$885.25M
Vanguard group	11.57M	9.87%	$778.45M
State street	5.02M	4.14%	$368.11M
Arrowstreet capital, limited partnership	3.29M	2.71%	$241.34M
Invesco	3.25M	2.67%	$238.04M
Morgan stanley	2.66M	2.27%	$178.90M
Geode capital management	2.43M	2.08%	$163.78M
Snyder capital management l p	2.40M	2.05%	$161.47M
Dimensional fund advisors lp	2.10M	1.80%	$141.61M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Koa wealth management	93.11K	4.30%	$6.27M
Cutter capital management, lp	120.00K	3.33%	$7.66M
Snyder capital management l p	2.40M	3.01%	$161.47M
Panoramic capital	89.43K	2.95%	$6.56M
Steamboat capital partners	142.58K	2.72%	$10.46M
2xideas	158.82K	2.46%	$11.65M
South street advisors	231.76K	2.19%	$15.60M
Bernzott capital advisors	67.79K	2.17%	$4.56M
Future fund	83.03K	1.77%	$5.59M
Mizuho markets americas	1.27M	1.65%	$85.38M

Top Buyers

Holder	Shares	% Assets	Change
Norges bank	1.90M	0.01%	1.90M
William blair investment management	1.84M	0.35%	1.84M
Voloridge investment management	1.06M	0.26%	1.06M
Mizuho markets americas	1.27M	1.65%	926.53K
Morgan stanley	2.66M	0.01%	920.70K

Top Sellers

Holder	Shares	% Assets	Change
Dld asset management, lp	-	-	-30.00M
Ubs group	1.37M	0.01%	-1.58M
Macquarie group	-	-	-1.55M
Frontier capital management	-	-	-1.27M
State street	5.02M	0.01%	-915.84K

New Positions

Holder	Shares	% Assets	Change	Value
Norges bank	1.90M	0.01%	1.90M	$128.20M
William blair investment management	1.84M	0.35%	1.84M	$124.03M
Voloridge investment management	1.06M	0.26%	1.06M	$77.59M
Bridgewater associates, lp	487.08K	0.14%	487.08K	$35.72M
Hotchkis & wiley capital management	134.63K	0.03%	134.63K	$9.87M

Sold Out

Holder	Change
Total investment management	-1.00
Harbor investment advisory	-4.00
Raleigh capital management	-6.00
Van hulzen asset management	-8.00
Southstate	-9.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	371	-39.58%	62,451,323	-58.49%	53	0.35%	186	-37.79%	135	-43.04%
Sep 30, 2025	351	-37.21%	58,910,289	-54.67%	48	0.42%	159	-40.67%	146	-31.78%
Jun 30, 2025	552	-1.08%	129,712,868	6.64%	106	1.10%	263	-16.51%	212	29.27%
Mar 31, 2025	15	-97.10%	5,085,362	-95.89%	4	0.04%	6	-97.75%	4	-97.75%
Dec 31, 2024	292	-43.41%	70,690,093	-43.61%	55	0.57%	130	-52.38%	114	-30.91%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	4.03M	3.27%	3.36K
iShares Core S&P Mid-Cap ETF	3.80M	3.22%	-238.20K
Vanguard Total Stock Mkt Idx Inv	3.70M	3.14%	8.13K
iShares Russell 2000 ETF	3.13M	2.54%	-
Vanguard Small Cap Index	2.66M	2.26%	-366.00
Aviva Investors GlConvtAbsRet I USD Acc	2.74M	2.16%	2.74M
SPDR® S&P Biotech ETF	2.18M	1.86%	4.86K
Delaware Small Cap Core I	1.74M	1.37%	-10.77K
State Street® SPDR® S&P® Biotech ETF	1.60M	1.36%	-8.57K
Vanguard Small Cap Growth Index Inv	1.48M	1.25%	-26.39K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 10, 2026	Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Sell	$599.09K
Mar 09, 2026	Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Sell	$143.33K
Mar 09, 2026	Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Sell	$1.21M
Mar 02, 2026	Torley Helen	PRESIDENT AND CEO	Sell	$1.07M
Mar 03, 2026	Torley Helen	PRESIDENT AND CEO	Sell	$928.17K

Insider Transactions Trends

Date	Buy	Sell
2027 Q1	-	-
2026 Q1	-	-
2025 Q4	-	13
2025 Q3	-	27
2025 Q2	-	7

HALO Ownership FAQ

Who Owns Halozyme Therapeutics?

Halozyme Therapeutics shareholders are primarily institutional investors at 53.28%, followed by 1.14% insiders and 45.58% retail investors. The average institutional ownership in Halozyme Therapeutics's industry, Biotech Stocks , is 381.47%, which Halozyme Therapeutics falls below.

Who owns the most shares of Halozyme Therapeutics?

Halozyme Therapeutics’s largest shareholders are Blackrock (17.62M shares, 13.88%), Blackrock funding, inc. /de (13.15M shares, 11.22%), and Vanguard group (11.57M shares, 9.87%). Together, they hold 34.97% of Halozyme Therapeutics’s total shares outstanding.

Does Blackrock own Halozyme Therapeutics?

Yes, BlackRock owns 13.88% of Halozyme Therapeutics, totaling 17.62M shares as of Jun 2024. This represents 0.02% of BlackRock's total assets, with a market value of 922.58M$. In the last quarter, BlackRock decreased its holdings by -622K shares, a -3.41% change.

Who is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested?

Koa wealth management is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.30% of its assets in 93.11K Halozyme Therapeutics shares, valued at 6.27M$.

Who is the top mutual fund holder of Halozyme Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Halozyme Therapeutics shares, with 3.27% of its total shares outstanding invested in 4.03M Halozyme Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools